Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
CDASI
Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
1 other identifier
observational
300
1 country
1
Brief Summary
The Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), established in 2008, is a one-site database study conducted at the University of Pennsylvania. The database has yielded valuable information and clinical insights into the pathophysiology, disease processes, including psychological responses, treatments and quality of life associated with dermatomyositis. The CDASI database incorporates the Cutaneous Dermatomyositis Disease Area and Severity Index), a validated outcome measure of disease responsiveness in patients, and other assessment tools, surveys and patient information to help validate the clinical course and quality of life of patients with dermatomyositis. The CDASI database has led to publication of comparison studies of CDASI and other clinical instruments and the effect of dermatomyositis on Quality of Life (QoL). The CDASI database is an ongoing resource that enables clinicians to evaluate the evolving clinical changes, treatment modalities and patient response to a challenging disease. Data will be analysed over a 5 years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2008
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedFirst Submitted
Initial submission to the registry
February 9, 2012
CompletedFirst Posted
Study publicly available on registry
October 26, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 2, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 2, 2030
March 30, 2026
March 1, 2026
21.6 years
February 9, 2012
March 24, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Cutaneous Dermatomyositis Disease Area and Severity Index
Disease severity tool
through study completion, an average of 1 year
Secondary Outcomes (1)
Skin quality of life tool
through study completion, an average of 1 year
Eligibility Criteria
Adult patients who have been diagnosed with dermatomyositis.
You may qualify if:
- Gender/Age: Males or females above 18 years old
- Diagnosis: Cutaneous Dermatomyositis
- Subjects able to give informed consent
You may not qualify if:
- Subjects without cutaneous DM
- Penn employees
- Penn students
- Cognitively impaired persons
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Biospecimen
Blood, skin tissue biopsies
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD and Principal Investigator
Study Record Dates
First Submitted
February 9, 2012
First Posted
October 26, 2016
Study Start
June 1, 2008
Primary Completion (Estimated)
January 2, 2030
Study Completion (Estimated)
January 2, 2030
Last Updated
March 30, 2026
Record last verified: 2026-03